A Phase I, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of HMPL-523 in Patients With Relapsed or Refractory Hematologic Malignancies

Trial Profile

A Phase I, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of HMPL-523 in Patients With Relapsed or Refractory Hematologic Malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 31 Jul 2017

At a glance

  • Drugs HMPL 523 (Primary)
  • Indications B cell lymphoma; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Sponsors Hutchison MediPharma
  • Most Recent Events

    • 31 Jul 2017 According to a Chi Medi media release, preliminary efficacy data expected in H2 2017 or H1 2018.
    • 10 Jan 2017 According to a Chi Medi media release, this trial is expected to complete dose-escalation in the first half of 2017.
    • 06 Dec 2016 According to a Chi-Med media release, data of healthy volunteers in Australia was recently presented at the 2016 Annual Meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top